Incidence of Central Nervous System Toxicity and Cytokine Release Syndrome in Leukemia Patients Treated with Blinatumomab

Blinatumoab公司 细胞因子释放综合征 医学 不良事件通用术语标准 累积发病率 毒性 白血病 免疫学 内科学 癌症 淋巴细胞白血病 免疫疗法 移植 嵌合抗原受体
作者
Elias Jabbour,Shilpa Paul,Dan E. Nichols,Faezeh Darbaniyan,Jenessa Lee,Koji Sasaki,Nicholas J. Short,Nitin Jain,Farhad Ravandi,Guillermo Garcia‐Manero,Tapan M. Kadia,Guillermo Montalban‐Bravo,G. Borthakur,Rebecca Garris,Marina Konopleva,Hagop M. Kantarjian
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 11663-11665 被引量:6
标识
DOI:10.1182/blood-2022-170579
摘要

INTRODUCTION Blinatumomab (BLINA) is a bispecific antibody construct that directs cytolytic T-cells to CD19 expressing B-cells resulting in proliferation of T-cells. It has potent activity in B-cell acute lymphoblastic leukemia (B-ALL) and chronic myeloid leukemia in lymphoid blast phase (CML-BP) and is associated with a risk of central nervous system toxicity (CNS tox) and cytokine release syndrome (CRS). Here we report the incidence, severity, and management of CNS tox and CRS in patients with B-ALL and CML-BP who received BLINA in a real-world setting. METHODS We retrospectively evaluated pts ≥18 years old with B-ALL or CML-BP treated with BLINA from 2016 to 2020 at MD Anderson Cancer Center. CNS tox and CRS were graded per CTACEv5 (Common Terminology Criteria for Adverse Events). CNS tox excluded headache. The primary objective was to evaluate the incidence of CNS tox and CRS. Secondary objectives included evaluation of toxicity severity, time to toxicity, duration of toxicity, and management of toxicity. Risk factors for toxicity were assessed in a multivariate analysis. RESULTS A total of 265 patients (pt) met eligibility criteria. Their median age was 45 years (range, 18-84 years) and 155 (58%) were male (Figures 1A). The cumulative number of BLINA cycles was 754 with a median of 2 cycles per pt (range, 1-11). Sixty-five pts (25%) received BLINA as part of frontline therapy with an overall median number of 1 prior therapy. Prior to starting BLINA, 43 pts (24%) had ≥20% bone marrow blasts and 124 pts (47%) were minimal residual disease (MRD) negative. Ten pts (4%) had active CNS disease before BLINA initiation, 27 pts (10%) had a history of prior CNS disease. A dose ramp-up was performed in 279 BLINA cycles (37%). During these cycles, dose escalation occurred on a median of day 8 (range, 2-17). Eighty-eight pts (33%) experienced CNS tox while receiving BLINA. CNS tox occurred during 15% (114) of all BLINA cycles and were classified as grade 1, 2, 3, and 4 or greater during 46 (40%), 37 (32%), 28 (25%), and 3 cycles (3%), respectively. Seventy CNS tox cases (61%) occurred during cycle 1, 29 (25%) during cycle 2, and 15 (13%) during cycle 3 or beyond (Figure 1B). Of the CNS tox cases occurring after cycle 1, 23 (52%) had CNS tox during a previous cycle. Median time to onset of CNS tox was 4 days (range, 1-25), median duration of CNS tox was 3 days (range, 1-28). Common symptoms of CNS tox included tremor (n=57), confusion (n=47), weakness (n=11), aphasia (n=9), and gait disturbance (n=8). Of the 114 cycles in which CNS tox occurred, 97 (85%) were managed with steroids. BLINA was held during 71 cycles due to CNS tox (62%) and dose-reduced during 44 cycles (39%). Thirteen cycles with CNS tox (11%) required no intervention. Of the 114 cycles with CNS tox, 66 (58%) were followed by additional cycles of BLINA. Pts who experienced CNS tox received a similar total number of BLINA cycles (median, 2) as pts who did not (median, 2). Pts who experienced CNS tox had a similar median overall survival (1.5 years) to those who did not (1.6 years). Notably, 51% of pts with active CNS disease or a prior history of CNS disease experienced CNS tox compared with 30% of pts without CNS disease. Preliminary multivariate logistic regression identified age, gender, and MRD positivity as risk factors for CNS tox. Ninety-four pts (35%) experienced CRS. CRS occurred during 115 cycles (15%), of which 36 (31%) were in the setting of a confirmed infection. CRS was classified as grade 1, 2, or 3 during 85 (74%), 23 (20%), and 7 cycles (6%), respectively. Eighty-two CRS cases (71%) occurred during cycle 1, 24 (21%) during cycle 2, and 9 (8%) during cycle 3 or beyond (Figure 1B). Of the CRS cases occurring after cycle 1, 19 (58%) had CRS during a previous cycle. Median onset of CRS was 3 days (range, 1-22), median duration of CRS was 2 days (range, 1-14). CRS was managed with steroids during 83 cycles (72%). BLINA was held during 56 cycles due to CRS (49%) and dose-reduced during 21 cycles (18%). Twenty-six cycles with CRS (23%) required no intervention. Of the 115 cycles with CRS, 79 (69%) were followed by additional cycles of BLINA. CONCLUSION CNS tox and CRS occurred in 33% and 35% of pts treated with BLINA and in 15% and 15% of BLINA cycles, respectively. With steroids and therapy modification, most pts who experienced toxicity were able to continue BLINA treatment while exhibiting similar outcomes to those without toxicity. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ding的应助被丫丫仁采纳,获得10
刚刚
情怀的应助被优美的冷雪采纳,获得10
1秒前
可爱的函函的应助被积极鱼采纳,获得10
1秒前
2秒前
甜甜天德发布了新的文献求助10
2秒前
3秒前
mm发布了新的文献求助30
3秒前
brokey完成签到,获得积分10
3秒前
888发布了新的文献求助10
7秒前
下小雨完成签到,获得积分10
7秒前
8秒前
个性向卉发布了新的文献求助10
8秒前
8秒前
8秒前
打打的应助被丹丹采纳,获得10
9秒前
10秒前
zuo20050727发布了新的文献求助10
10秒前
10秒前
orixero的应助被WYL采纳,获得10
10秒前
11秒前
GIN的应助被浮云采纳,获得20
11秒前
12秒前
zuo20050727发布了新的文献求助10
12秒前
12秒前
弗洛伊德的梦完成签到,获得积分10
12秒前
内向盼秋完成签到,获得积分10
13秒前
zuo20050727发布了新的文献求助10
13秒前
1asfdwe完成签到 ,获得积分10
13秒前
13秒前
13秒前
zuo20050727发布了新的文献求助10
13秒前
zuo20050727发布了新的文献求助20
13秒前
积极鱼发布了新的文献求助10
14秒前
hkp发布了新的文献求助10
14秒前
niko发布了新的文献求助10
15秒前
15秒前
优秀的老虎完成签到,获得积分10
15秒前
15秒前
西哥完成签到,获得积分10
16秒前
zuo20050727发布了新的文献求助10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193361
求助须知:如何正确求助?哪些是违规求助? 9579602
关于积分的说明 21866201
捐赠科研通 7792983
什么是DOI,文献DOI怎么找? 3437263
关于科研通互助平台的介绍 2560718
邀请新用户注册赠送积分活动 2484082